←
Ryan Agas121 posts
Ryan Agas avatar

Ryan Agas

@ryanagasmd

Asst Prof @USTFMSofficial + GI RadOnc @USThospital + RadOnc Residency Training Officer @CardinalSantos🇵🇭 | Former GI/Sarc fellow @PeterMacRadOnc🇦🇺

◷ Joined August 2015▧ 5 Photos and videos
Krishan Jethwa avatar
⟳ Ryan Agas retweeted
Krishan Jethwa@KrishanJethwa·Oct 22

🔥AGITG MASTERPLAN🔥 Borderline resectable or Locally advanced PDAC n=75 🔍Randomized 3m mFOLFIRINOX or Gem+nab-Paclitaxel alone +/- SBRT (40 Gy/5 fx) Primary endpoint: locoregional recurrence 🚨SBRT had improved: ✅12 m LRR: 20% vs. 50% ✅mOS 22m vs. 14 m #ESMO26

Post attachment
Erman Akkus avatar
⟳ Ryan Agas retweeted
Erman Akkus@Erman_Akkus·Sep 25

Microwave ablation versus stereotactic body radiotherapy for oligometastatic colorectal liver metastases (LAVA-CRLM): a prospective, randomised, phase II trial thelancet.com/journals/lanep…

Syed A. Ahmad avatar
⟳ Ryan Agas retweeted
Syed A. Ahmad@SyedAAhmad5·Mar 14

Stereotactic body radiotherapy versus hepatic resection for recurrent small hepatocellular carcinoma: A post-hoc analysis with propensity score adjustment from two randomized trials - European Journal of Cancer ejcancer.com/article/S0959-8…

Oscar Tahuahua avatar
⟳ Ryan Agas retweeted
Oscar Tahuahua@drtahuahua·Feb 17

Recent advancements in radiotherapy for hepatocellular carcinoma For years, RT played only a limited role in HCC management. Today, SBRT can achieve >90% 2 year local control with RILD <5% (Radiation-Induced Liver Disease) Proton therapy reports ~88% 3-year local control with low hepatic toxicity. Not universally adopted, but difficult to ignore with modern data. esmogastro.org/article/S2949… @OncoAlert

Post attachmentPost attachment
Ryan Agas avatar
Ryan Agas@ryanagasmd·Jan 30

Always honored to be part of the expert panel at the PCS Liver Multidisciplinary Tumor Board—especially alongside the esteemed @hpbsurgeon1 Dr. Catherine Teh. Grateful for the opportunity to contribute to such meaningful discussions. #GIradonc

Post attachment
Dr. Nina Niu Sanford avatar
⟳ Ryan Agas retweeted
Dr. Nina Niu Sanford@NiuSanford·Jan 10

PLATO ACT5 Ph3 RCT (n=463): 53.2 v 58.8 v 61.6 Gy in T3-4/N+ anal SCC. No early benefit to dose escalation w similar cCR (65-67%) across dose levels. More uniform RT dose is not the answer – need better stratification, bio-driven personalization, RT/systemic integration. #GI26

Post attachmentPost attachmentPost attachmentPost attachment
Advances, an ASTRO Journal avatar
⟳ Ryan Agas retweeted
Advances, an ASTRO Journal@Advances_ASTRO·20 Nov 2025

Ever thought about 🔄️re-irradiation for squamous cell carcinoma of the anal canal? Turns out... it can be done! Thanks to this ⏪retrospective study of 35 patients by @jordan_McD3 @ThatDamDoc @PrajnanDasMD @eugenekoay @ebludmir @Snoticewala @VanMorrisMD @DrEmmaHolliday @MDAndersonNews ⚡ Hyperfractionated re-RT (1.5 Gy BID, ~39 Gy (30 - 51 Gy range)) delivered: 🎯 46% cCR in recurrences 🌟 78% cCR in new primaries after prior pelvic RT 💥 Durable pelvic control in a truly tough population 🩺 Acute toxicity was similar to standard CRT (23%), and keeping dose ≤39 Gy may help avoid major late effects. 🤔There appeared to be an association with field size and rates of late toxicity! Got any of your own experiences to share? advancesradonc.org/article/S… @ASTRO_org

Giovanni Marchegiani avatar
⟳ Ryan Agas retweeted
Giovanni Marchegiani@Gio_Marchegiani·13 Oct 2025

The kiss 💋 between nab-paclitaxel / gem and FOLFINIRNOX ?! ♥️ Neoadjuvant regimens combined in resectable 💉 RCT 324 pts vs. Upfront surgery median EFS 15 vs. 10 months? 🧐 Doubts about control group, but again in the direction of neoadjuvant to all! cell.com/action/showPdf?pii=…

Post attachmentPost attachmentPost attachment
Dr Rishabh Jain avatar
⟳ Ryan Agas retweeted
Dr Rishabh Jain@DrRishabhOnco·12 Oct 2025

🧠 You can shrink the tumour—but not the tumour bed. New RAPIDO analysis in BJS 2025 shows why small margins after TNT can turn dangerous 👇 💡 Trial: RAPIDO (n = 920, LARC) 🎯 TNT = 5×5 Gy + 6 CAPOX / 9 FOLFOX → TME vs CRT = 25–28×1.8–2 Gy + capecitabine → TME 📊 8-year results: • LRR 10.8% (TNT) vs 5.8% (CRT) → HR 1.91 • Spike seen only after sphincter-preserving surgery (SPS)  → 12.1% (TNT) vs 4.8% (CRT) (HR 2.6) • 🚨 If distal margin ≤ 10 mm → 25.4% (TNT) vs 1.8% (CRT) 💥 (HR 15.5) 🔍 Why? TNT causes tumour shrinkage but leaves scattered viable cells in the original tumour bed. ✂️ Cutting “too close” (<1 cm) may slice through microscopic disease → higher local recurrence. 🇸🇪🇳🇱 Geography tells the story: Sweden = more APR → no difference Netherlands = more SPS & tight margins → higher TNT LRR 🩻 Takeaway: TNT reduces distant mets ✅ but may raise local relapse if DRM ≤ 1 cm ⚠️ ➡️ Surgeons must factor in baseline tumour bed, not just post-TNT shrinkage. 📖 Prata I et al. Br J Surg 2025 🔗 doi.org/10.1093/bjs/znaf190 #OncoTwitter #ColorectalCancer #RectalCancer #RadOnc #Surgery @OncoAlert @esmo_open @BJSurgery @myESMO

Post attachment